Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis ...

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

Learn more about whether AbbVie Inc. or Genmab A/S is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Driven by Biopharmaceutical Innovations and Gene Therapies, the market Booms Amidst Growing Incidence of Hemophilia and Von Willebrand Disease ...